BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

GlaxoSmithKline (GSK) to File GLP-1 Diabetes Drug Albiglutide as Data Impresses


4/3/2012 7:50:05 AM

GlaxoSmithKline will push ahead with plans to file its experimental once-weekly diabetes drug albiglutide for regulatory approval, following the read-out from a series of clinical trials. Albiglutide belongs to the same class of injectable GLP-1 medicines as Novo Nordisk's Victoza and Byetta, from Amylin Pharmaceuticals and Eli Lilly. Byetta was the first drug of the type. Last November, GSK reported that albiglutide cut blood sugar less than daily Victoza in the first of a series of late-stage clinical trials, dimming its prospects in an increasingly competitive market.

Read at Fox News
Read at News Release
Read at RTT News
Read at Reuters
Read at Pharma Times [Free Reg Req'd]

   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->